HCW Biologics (HCWB) Net Income towards Common Stockholders (2020 - 2025)

HCW Biologics (HCWB) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$3.5 million in Q4 2025.

• Quarterly Net Income towards Common Stockholders fell 2.75% year-over-year to -$3.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$22.3 million (up 25.71% YoY) and the FY2025 annual result came in at -$22.3 million, up 25.73% from the prior year.
• Net Income towards Common Stockholders climbed to -$3.5 million in Q4 2025, from -$4.6 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$2.1 million in Q1 2022 to a low of -$15.3 million in Q2 2024.
• A 5-year average of -$5.6 million and a median of -$4.1 million in 2021 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders sank 294.5% — and 2025, when it soared 70.35%.
• Tracing HCWB's Net Income towards Common Stockholders over 5 years: stood at -$3.2 million in 2021, then tumbled by 81.56% to -$5.8 million in 2022, then sank by 86.87% to -$10.8 million in 2023, then jumped by 68.67% to -$3.4 million in 2024, then slipped by 2.75% to -$3.5 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$3.5 million (Q4 2025), -$4.6 million (Q3 2025), and -$12.1 million (Q2 2025), per Business Quant data.